| STUDY00000897 | EMPA on urine adenine-creatinine ratio | Allen S. Anderson, MD | This study evaluates the effects of SGLT2i or Sodium-Glucose Cotransporter-2 inhibitors in reducing endogenous adenine in patients with CKD admitted to hospital with heart failure. | nath@uthscsa.edu |
| STUDY00001998 | Spatial metabolomics of Dense Deposit Disease – a case study | Kumar Sharma, MD | The objective of this study is to perform spatial metabolomics and transcriptomics of kidney biopsy tissues to further characterize the disease pathology of dense deposit disease – a rare complement-mediated kidney disease. | nath@uthscsa.edu |
| Post Hoc Analysis | Impact of sotagliflozin on endogenous urine adenine levels | Kumar Sharma, MD | This post-hoc analysis will answer whether sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, reduced endogenous adenine measured in urine collected prospectively in the SOLOIST-WHF trial. | nath@uthscsa.edu |
| 20210436HU | Metabolomic study in renal biopsy specimens | Swetha R. Kanduri, MD | To establish untargeted and targeted spatial metabolomics and other basic analysis of tissues from renal and other organ biopsies to assess cellular metabolic states associated with healthy function, activation of disease, acute injury, chronic condition, and recovery. | nath@uthscsa.edu |
| STUDY00000814 | BRISK: Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis | Subrata Debnath, Ph.D. | This study evaluates the feasibility and efficacy of bupropion for the treatment of fatigue in patients with end-stage kidney disease on maintenance hemodialysis. Active metabolites of bupropion and their kinetics will be measured at the CPM. | https://clinicaltrials.gov/study/NCT06609343 |
| 20220558HU | OASIS: Oral intradialytic amino acids supplementation to vitalize end-stage kidney disease patients on hemodialysis | Subrata Debnath, Ph.D. | The study tests and compares the efficacy of essential amino acid valine or essential amino acids in reducing fatigue, frailty, and cognitive function in end-stage kidney disease patients undergoing hemodialysis treatment. CPM Laboratory performs targeted metabolomics in plasma. | https://clinicaltrials.gov/study/NCT05705414 |
| Branched-chain Amino Acids to Improve Sarcopenia in Patients with Advanced Chronic Kidney Disease. | Subrata Debnath, Ph.D. | The objective of this study is to evaluate the feasibility, safety, and therapeutic benefits of isolated oral valine compared to essential amino acid supplementation in improving sarcopenia in patients with stage 5 CKD. CPM laboratory will perform the targeted metabolomics in collected biological fluids – urine and plasma. In addition, bulk, spatial metabolomics, and transcriptomics will be conducted to characterize muscle architecture before and after intervention. | nath@uthscsa.edu |
| | | | |
